Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy Journal Article


Authors: Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; Rosenberg, J.; Voss, M. H.; Rudin, C. M.; Rizvi, H.; Hou, X.; Rodriguez, K.; Albano, M.; Gordon, R. A.; Leduc, C.; Rekhtman, N.; Harris, B.; Menzies, A. M.; Guminski, A. D.; Carlino, M. S.; Kong, B. Y.; Wolchok, J. D.; Postow, M. A.; Long, G. V.; Hellmann, M. D.
Article Title: Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
Abstract: Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti-programmed death-1 (PD-1)/ programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti-PD-1/PD-L1 monotherapy or in combination with anti-cytotoxic T-cell lymphocyte-4mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia: melanomas only, 2013 to 2015). Pneumonitis was diagnosed by the treating investigator; cases with confirmed malignant lung infiltration or infection were excluded. Clinical, radiologic, and pathologic features of pneumonitis were collected. Associations among pneumonitis incidence, therapy received, and underlyingmalignancywere examined with Fisher's exact test as were associations between pneumonitis features and outcomes. Results Of 915 patientswho received anti-PD-1/PD-L1mAbs, pneumonitis developed in 43 (5%; 95%CI, 3%to 6%; Memorial Sloan Kettering Cancer Center, 27 of 578 [5%]; Melanoma Institute of Australia, 16 of 337 [5%]). Time to onset of pneumonitis ranged from9 days to 19.2months. The incidence of pneumonitis was higher with combination immunotherapy versus monotherapy (19 of 199 [10%] v 24 of 716 [3%]; P , .01). Incidencewas similar in patientswithmelanoma and non-small-cell lung cancer (overall, 26 of 532 [5%] v nine of 209 [4%]; monotherapy, 15 of 417 v five of 152 [P = 1.0]; combination, 11 of 115 v four of 57 [P = .78]). Seventy-two percent (31 of 43) of caseswere grade 1 to 2, and 86%(37 of 43) improved/resolved with drug holding/immunosuppression. Five patients worsened clinically and died during the course of pneumonitis treatment; proximal cause of deathwas pneumonitis (n = 1), infection related to immunosuppression (n = 3), or progressive cancer (n = 1). Radiologic and pathologic features of pneumonitis were diverse. Conclusion Pneumonitis associated with anti-PD-1/PD-L1 mAbs is a toxicity of variable onset and clinical, radiologic, and pathologic appearances. It is more common when anti-PD-1/PD-L1 mAbs are combined with anti-cytotoxic T-cell lymphocyte-4 mAb. Most events are low grade and improve/ resolve with drug holding/immunosuppression. Rarely, pneumonitis worsens despite immunosuppression, and may result in infection and/or death. © 2016 by American Society of Clinical Oncology.
Journal Title: Journal of Clinical Oncology
Volume: 35
Issue: 7
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2017-03-01
Start Page: 709
End Page: 717
Language: English
DOI: 10.1200/jco.2016.68.2005
PROVIDER: scopus
PUBMED: 27646942
PMCID: PMC5559901
DOI/URL:
Notes: Article -- Export Date: 3 April 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Natasha Rekhtman
    208 Rekhtman
  2. Jedd D Wolchok
    607 Wolchok
  3. Neil Howard Segal
    94 Segal
  4. Michael Andrew Postow
    175 Postow
  5. Martin Henner Voss
    123 Voss
  6. Jamie Erin Chaft
    120 Chaft
  7. Ruth-Ann Roman
    26 Roman
  8. Alexander Meyer Lesokhin
    106 Lesokhin
  9. Matthew David Hellmann
    147 Hellmann
  10. Jonathan Eric Rosenberg
    210 Rosenberg
  11. Charles Rudin
    155 Rudin
  12. Jarushka Naidoo
    29 Naidoo
  13. Kaitlin Marie Woo
    97 Woo
  14. Charles   Leduc
    13 Leduc
  15. Bianca   Harris
    6 Harris
  16. Hira Abbas Rizvi
    18 Rizvi
  17. Xue Hou
    1 Hou